Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT06110637
Other study ID # 21CH248
Secondary ID 2022-A00219-34
Status Completed
Phase N/A
First received
Last updated
Start date June 15, 2022
Est. completion date January 6, 2023

Study information

Verified date November 2023
Source Centre Hospitalier Universitaire de Saint Etienne
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

During running, each contact between the foot and the ground causes an impact. Ground reaction forces (GRF) are considered as an input into the musculoskeletal system. It involves a sudden deceleration in the lower limb packages (including muscles) which generates Soft-Tissue Vibrations (STV). The body is able to attenuate Soft-Tissue Vibrations (STV) but this capability decreases with fatigue. STV could be minimize by improving shoe midsole hardness.


Description:

Only 4 studies have studied Soft-Tissue Vibrations (STV) with a distance not exceeding 10 km and without evaluating the potential influence of the shoe. Thus, the effects of shoe midsole hardness on Soft-Tissue Vibrations (STV) and neuromuscular fatigue at the end of an intense and/or long run remains unknown. The purpose is to compare two shoes whose only midsole hardness differs during a half-marathon on Soft-Tissue Vibrations (STV), neuromuscular fatigue and running kinetics. Maybe the shoe ensuring a better STV damping of the medial gastrocnemius muscle would reduce neuromuscular fatigue and improve comfort.


Recruitment information / eligibility

Status Completed
Enrollment 20
Est. completion date January 6, 2023
Est. primary completion date December 15, 2022
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Male
Age group 18 Years to 65 Years
Eligibility Inclusion Criteria: - Endurance runners doing a long run of at least 20 km once a week. - Affiliated or beneficiaries of a social security plan. - Have freely given their written consent. - Not participating in a competition during the study period. - Shoe size 37 to 46 Exclusion Criteria: - Any subject who has been injured in the 3 months preceding the protocol - Any subject with chronic joint pathologies (e.g., repeated sprains, patellar or ligament problems) or cardiac pathologies. - Any subject with chronic or central neurological pathologies - Any subject participating at the same time in another medical interventional experiment - Any subject who has taken corticosteroids within 3 months (inhalation, infiltration or history of prolonged corticosteroid therapy). - Any subject deprived of liberty or under legal protection (guardianship, curatorship, safeguard of justice, family habilitation). - Any subject declaring to have taken products prohibited by the World Anti-Doping Agency

Study Design


Related Conditions & MeSH terms


Intervention

Other:
"hard shoes" runners evaluation
The "hard shoes" runners get on the treadmill for 21 km at a speed corresponding to 70 percent (%) of their the maximum aerobic speed (MAV) and are evaluated.
"Soft shoes" runners evaluation
The "soft shoes" runners get on the treadmill for 21 km at a speed corresponding to 70 percent (%) of their the maximum aerobic speed (MAV) and are evaluated.

Locations

Country Name City State
France Centre Hospitalier Universitaire de Saint-Etienne Saint-Étienne

Sponsors (1)

Lead Sponsor Collaborator
Centre Hospitalier Universitaire de Saint Etienne

Country where clinical trial is conducted

France, 

Outcome

Type Measure Description Time frame Safety issue
Primary Change of the damping coefficient (in percent %). The main evaluation criterion will be the relative variation (in percent %) of the damping coefficient (in /s) of the medial gastrocnemius muscle measured with an accelerometer, at the beginning (the first five minutes) and at the end (the last five minutes) of 21 km at a speed corresponding to 70% of the maximum aerobic speed (MAS) on a treadmill, carried out by experienced amateurs during two shoe conditions: soft and firm sole. From the beginning to the end of the 21 km race.
Secondary Temporal evolution of vibrations measurements. The relative variation (in percent %) of the damping coefficient (in /s) of the medial gastrocnemius muscle will be measured with an accelerometer every 3 km at a speed corresponding to 70% of the maximum aerobic speed (MAS) on a treadmill, carried out by confirmed amateurs during the two shoe conditions.
For this outcome, it is not possible to use an unit of time, because the time of the measurements are define only by the distance covered by the subject.
Kilometers : 1st, 3rd, 6th, 9th, 12th, 15th, 18th, 21st
Secondary Evaluation of improved vibration damping on neuromuscular fatigue : isometric force The relative change (in percent %) in the maximum isometric force (in Newton) of the ankle plantar flexors before and after the 21 km From the beginning to the end of the 21 km race.
Secondary Evaluation of improved vibration damping on neuromuscular fatigue : jerk amplitude. The relative change (in percent %) in jerk amplitudes measured by electrically evoked force (in Newton) after isometric contraction of the plantar flexors of the ankle, before and after the 21 km. From the beginning to the end of the 21 km race.
Secondary Evaluation of improved vibration damping on neuromuscular fatigue : level of voluntary activation. The relative change (percent %) in the maximum level of voluntary activation (percent %) measured in isometric mode of the plantar flexors of the ankle before and after the 21 km From the beginning to the end of the 21 km race.
Secondary Evaluation of improved vibration damping on neuromuscular fatigue : plantar flexors. The relative change (in percent %) in the maximum isometric force (in Newton) of the plantar flexors of the toes before and after the 21 km. From the beginning to the end of the 21 km race.
Secondary Biomechanical parameters measurement : Ground reaction forces (Newton) Ground reaction forces (in Newton, measured by treadmill force platforms).
For this outcome, it is not possible to use an unit of time, because the time of the measurements are define only by the distance covered by the subject.
Kilometers : 1st, 3rd, 6th, 9th, 12th, 15th, 18th, 21st.
Secondary Biomechanical parameters measurement : Spatio-temporal parameters (second) Spatio-temporal parameters: contact time (CT) and flight time (TV)
For this outcome, it is not possible to use an unit of time, because the time of the measurements are define only by the distance covered by the subject.
Kilometers : 1st, 3rd, 6th, 9th, 12th, 15th, 18th, 21st.
Secondary Temporal evolution of the energy cost measurement This will be the relative variation (in percent %) of the energy cost (in J/kg/m), measured continuously thanks to a portable gas exchange measurement system (ergo spirometer Metamax 3B®, Cortex Medical, Leipzig, Germany), at a speed corresponding to 70% of the maximum aerobic speed (MAS) on a treadmill, carried out by experienced amateurs during the two shoe conditions. From the beginning to the end of the 21 km race.
See also
  Status Clinical Trial Phase
Completed NCT05001152 - Taste Assessment of Ozanimod Phase 1
Completed NCT05029518 - 3-Way Crossover Study to Compare the PK (Pharmokinetics) and to Evaluate the Effect of Food on the Bioavailability Phase 1
Completed NCT04493255 - A Study to Determine the Metabolism and Elimination of [14C]E7090 in Healthy Male Participants Phase 1
Completed NCT03457649 - IV Dose Study to Assess the Safety, Tolerability, PK, PD and Immunogenicity of ARGX-113 in Healthy Volunteers Phase 1
Completed NCT00995891 - Collection of Blood, Bone Marrow, and Buccal Mucosa Samples From Healthy Volunteers for Center for Human Immunology, Autoimmunity, and Inflammatory Diseases (CHI) Laboratory Research Studies
Completed NCT05050318 - Annual Study for Collection of Serum Samples in Children and Older Adults Receiving the 2021-2022 Formulations of Fluzone Quadrivalent Vaccine and Fluzone High-Dose Quadrivalent Vaccine, Respectively Phase 4
Completed NCT05043766 - Evaluation of Oral PF614 Relative to OxyContin Phase 1
Completed NCT04466748 - A Multiple Ascending Dose Pharmacology Study of Anaprazole in Healthy Chinese Subjects Phase 1
Completed NCT00746733 - Vyvanse and Adderall XR Given Alone and in Combination With Prilosec OTC Phase 1
Recruiting NCT05929651 - Study of Immunogenicity and Safety of MenQuadfi® as a Booster Vaccine in Toddlers 12 to 23 Months, Regardless of the Quadrivalent Meningococcal Conjugate Vaccine Used for Priming in Infancy Phase 4
Completed NCT05954039 - Evaluation of the Efficacy of a Dietary Supplement on Hair Loss and Hair Aspect N/A
Completed NCT05045716 - A Study of Subcutaneous Lecanemab in Healthy Participants Phase 1
Active, not recruiting NCT02747927 - Efficacy, Safety and Immunogenicity of Takeda's Tetravalent Dengue Vaccine (TDV) in Healthy Children Phase 3
Completed NCT05533801 - A Study to Demonstrate the Bioequivalence of Lecanemab Supplied in Vials and a Single-Use Auto-Injector (AI) in Healthy Participants Phase 1
Not yet recruiting NCT03931369 - Adaptation of Thirst to a Single Administration of Tolvaptan (TOLVATHIRST) Phase 2
Completed NCT03279146 - A Single Dose Study Evaluating PK of TXL Oral Formulations in Healthy Subjects Phase 1
Completed NCT06027437 - A Study to Assess the Relative Biological Availability and the Effect of Food on the Drug Levels of Danicamtiv in Healthy Adult Participants Phase 1
Recruiting NCT05619874 - Effects of Two Virtual HIFCT Programs in Adults With Abdominal Obesity N/A
Completed NCT05553418 - Investigational On-body Injector Clinical Study N/A
Completed NCT04092712 - Study Evaluating Pharmacokinetics and Mass Balance of [14C]-CTP-543 in Healthy Adult Male Volunteers Phase 1